FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W137122611> ?p ?o ?g. }

• W137122611 endingPage "538" @default.
• W137122611 startingPage "538" @default.
• W137122611 abstract "Abstract Background An irreversible proteasome inhibitor with decreased peripheral neuropathy compared to bortezomib, Carfilzomib (Cz) has potent anti-MM effects resulting in deep clinical responses and durable remissions. In this two-stage phase II trial of 45 planned patients, we treat newly diagnosed MM patients with Cz, lenalidomide(Ln), and dexamethasone (Dx) followed by 2 years of Ln maintenance. Methods Eight 28-day cycles of combination therapy comprises: Cz IV 20/36 mg/m2 on days 1, 2, 8, 9, 15, 16; Ln oral 25 mg days 1-21; and Dx IV or oral 20/10 mg (C1-4/5-8) on days 1, 2, 8, 9, 15, 16, 22, 23. Transplant eligible patients undergo stem cell collection after 4 cycles of CRd and continue with treatment. After 8 cycles of combination therapy, patients with SD or better receive up to 24 cycles of Ln extended dosing 10 mg days 1-21. Primary endpoint is ≥ grade 3 neuropathy. Bone marrow samples are collected at baseline, C1D2 (single agent Cz exposed), CR/end of cycle 8 (cycles 1-8), CR/end of cycle 20 (cycles 9-20), and CR/end of cycle 32/treatment termination (cycles 21-32). Patients are evaluated for clinical biomarkers, FDG-PET CT, and MRD studies (flow cytometry and PCR) at regular time points. Flow cytometry utilizes 8-color flow panel and analyzes ≥ 3 x 106 events (sensitivity 1 x 10-5). Results Forty-one patients meeting eligibility criteria have been enrolled (24 male, 17 female; median age 60; range 40-88). Among patients enrolled, median M-spike is 2.9 (1.0-7.6 g/dL) and isotypes included 26-IgG, 10 – IgA, 4 – free kappa, and 1 – free lambda. Thirty-eight patients are evaluable for response and toxicity. No patients have had ≥ grade 3 neuropathy. The mean decline in serum M-protein (n=33) was 72% after 1 cycle of CRd received. Best responses after a median of 9 cycles (range 2-20) completed, include 17–sCR/1-CR/6-nCR (63%), 10-VGPR (26%), 3-PR (8%), and 1-SD (3%). Among 18/38 (47%), median time to sCR/CR was 5 cycles. Among 14 CR/sCR + 3 nCR patients who underwent MRD assessment, all were negative. Among patients with ≤ VGPR at the end of 8 cycles of CRd, 5/8 (63%) had evidence of immunophenotypically abnormal plasma cells defined by flow cytometry, and 3 patients had undetectable abnormal plasma cells (1 achieved sCR after 8 additional Ln cycles). After median follow-up of 10 months (3-22), PFS rate was 83.3%. Twenty-five patients have completed 8 cycles of CRd, while 24/25 continued to Ln extension and 1 patient opted to exit study after CRd. Patients with non-hematologic toxicity events (≥ grade 3) include: electrolyte disturbances - 7(18%), LFT elevation - 5(13%), rash/pruritus – 4(11%), fatigue – 4(11%), cardiovascular – 3(8%), dyspnea/respiratory – 3(8%), constitutional symptoms – 2(5%), infections – 2(5%), VTE - 2(5%), and anxiety – 1(3%). Patients with hematologic toxicity events (≥ grade 3) include: lymphopenia –24(63%), anemia – 6(16%), leukopenia - 5(13%), and thrombocytopenia - 4(11%). All patients with baseline FDG avid lesions or extramedullary disease showed decrease or resolution of FDG avidity at MRD assessment time points. Conclusions Beyond traditional clinical response criteria, using a functional imaging and highly sensitive MRD assays, we consistently show high rates of deep remission and MRD negativity among newly diagnosed MM patients treated with carfilzomib, revlimid, dexamethasone (CRd) combination therapy. The results were very similar across age-groups and the oldest patient on this trial was 88 years old. If deep remissions are maintained with a delayed ASCT strategy incorporating extended dosing revlimid therapy, this may be a future strategy available to all patients irrespective of age. Disclosures: Off Label Use: Abstract is in newly diagnosed Multiple Myeloma patients. Carfilzomib is approved for relapsed/refractory patients." @default.
• W137122611 created "2016-06-24" @default.
• W137122611 creator A5010930696 @default.
• W137122611 creator A5014636271 @default.
• W137122611 creator A5016656825 @default.
• W137122611 creator A5017057018 @default.
• W137122611 creator A5025311144 @default.
• W137122611 creator A5044239219 @default.
• W137122611 creator A5044366730 @default.
• W137122611 creator A5044681793 @default.
• W137122611 creator A5045179755 @default.
• W137122611 creator A5046553822 @default.
• W137122611 creator A5046878636 @default.
• W137122611 creator A5048088566 @default.
• W137122611 creator A5048966043 @default.
• W137122611 creator A5058021865 @default.
• W137122611 creator A5060701531 @default.
• W137122611 creator A5061379753 @default.
• W137122611 creator A5062086023 @default.
• W137122611 creator A5064222660 @default.
• W137122611 creator A5065696086 @default.
• W137122611 creator A5067074464 @default.
• W137122611 creator A5079704265 @default.
• W137122611 creator A5081833588 @default.
• W137122611 creator A5081837203 @default.
• W137122611 creator A5082004555 @default.
• W137122611 creator A5082376289 @default.
• W137122611 creator A5086510250 @default.
• W137122611 creator A5089952063 @default.
• W137122611 date "2013-11-15" @default.
• W137122611 modified "2023-09-30" @default.
• W137122611 title "Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients" @default.
• W137122611 doi "https://doi.org/10.1182/blood.v122.21.538.538" @default.
• W137122611 hasPublicationYear "2013" @default.
• W137122611 type Work @default.
• W137122611 sameAs 137122611 @default.
• W137122611 citedByCount "29" @default.
• W137122611 countsByYear W1371226112013 @default.
• W137122611 countsByYear W1371226112014 @default.
• W137122611 countsByYear W1371226112015 @default.
• W137122611 countsByYear W1371226112016 @default.
• W137122611 countsByYear W1371226112017 @default.
• W137122611 countsByYear W1371226112018 @default.
• W137122611 countsByYear W1371226112019 @default.
• W137122611 countsByYear W1371226112020 @default.
• W137122611 countsByYear W1371226112021 @default.
• W137122611 countsByYear W1371226112022 @default.
• W137122611 crossrefType "journal-article" @default.
• W137122611 hasAuthorship W137122611A5010930696 @default.
• W137122611 hasAuthorship W137122611A5014636271 @default.
• W137122611 hasAuthorship W137122611A5016656825 @default.
• W137122611 hasAuthorship W137122611A5017057018 @default.
• W137122611 hasAuthorship W137122611A5025311144 @default.
• W137122611 hasAuthorship W137122611A5044239219 @default.
• W137122611 hasAuthorship W137122611A5044366730 @default.
• W137122611 hasAuthorship W137122611A5044681793 @default.
• W137122611 hasAuthorship W137122611A5045179755 @default.
• W137122611 hasAuthorship W137122611A5046553822 @default.
• W137122611 hasAuthorship W137122611A5046878636 @default.
• W137122611 hasAuthorship W137122611A5048088566 @default.
• W137122611 hasAuthorship W137122611A5048966043 @default.
• W137122611 hasAuthorship W137122611A5058021865 @default.
• W137122611 hasAuthorship W137122611A5060701531 @default.
• W137122611 hasAuthorship W137122611A5061379753 @default.
• W137122611 hasAuthorship W137122611A5062086023 @default.
• W137122611 hasAuthorship W137122611A5064222660 @default.
• W137122611 hasAuthorship W137122611A5065696086 @default.
• W137122611 hasAuthorship W137122611A5067074464 @default.
• W137122611 hasAuthorship W137122611A5079704265 @default.
• W137122611 hasAuthorship W137122611A5081833588 @default.
• W137122611 hasAuthorship W137122611A5081837203 @default.
• W137122611 hasAuthorship W137122611A5082004555 @default.
• W137122611 hasAuthorship W137122611A5082376289 @default.
• W137122611 hasAuthorship W137122611A5086510250 @default.
• W137122611 hasAuthorship W137122611A5089952063 @default.
• W137122611 hasConcept C126322002 @default.
• W137122611 hasConcept C126894567 @default.
• W137122611 hasConcept C141071460 @default.
• W137122611 hasConcept C203092338 @default.
• W137122611 hasConcept C2776063141 @default.
• W137122611 hasConcept C2776364478 @default.
• W137122611 hasConcept C2777288759 @default.
• W137122611 hasConcept C2777478702 @default.
• W137122611 hasConcept C2779609412 @default.
• W137122611 hasConcept C2780108899 @default.
• W137122611 hasConcept C2780401358 @default.
• W137122611 hasConcept C31760486 @default.
• W137122611 hasConcept C535046627 @default.
• W137122611 hasConcept C71924100 @default.
• W137122611 hasConcept C90924648 @default.
• W137122611 hasConceptScore W137122611C126322002 @default.
• W137122611 hasConceptScore W137122611C126894567 @default.
• W137122611 hasConceptScore W137122611C141071460 @default.
• W137122611 hasConceptScore W137122611C203092338 @default.
• W137122611 hasConceptScore W137122611C2776063141 @default.
• W137122611 hasConceptScore W137122611C2776364478 @default.
• W137122611 hasConceptScore W137122611C2777288759 @default.
• W137122611 hasConceptScore W137122611C2777478702 @default.

• next